RESUMEN
BACKGROUND: Aquaporin-2 (AQP2) is a key water channel protein which determines the water permeability of the collecting duct. Multiple phosphorylation sites are present at the C-terminal of AQP2 including S256 (serine at 256 residue), S261, S264 and S/T269, which are regulated by vasopressin (VP) to modulate AQP2 trafficking. As the dynamics of these phosphorylations have been studied mostly in rodents, little is known about the phosphorylation of human AQP2 which has unique T269 in the place of S269 of rodent AQP2. Because AQP2 is excreted in urinary exosomes, the phosphoprotein profile of human AQP2 can be easily examined through urinary exosomes without any intervention. METHODS: Human urinary exosomes digested with trypsin or glutamyl endopeptidase (Glu-C) were examined by the liquid chromatography coupled with tandem mass spectrometry (LC-MS/MS) phosphoproteomic analysis. RESULTS: The most dominant phosphorylated AQP2 peptide identified was S256 phosphorylated form (pS256), followed by pS261 with less pS264 and far less pT269, which was confirmed by the western blot analyses using phosphorylated AQP2-specific antibodies. In a patient lacking circulating VP, administration of a VP analogue showed a transient increase (peak at 30-60 min) in excretion of exosomes with pS261 AQP2. CONCLUSION: These data suggest that all phosphorylation sites of human AQP2 including T269 are phosphorylated and phosphorylations at S256 and S261 may play a dominant role in the urinary exosomal excretion of AQP2.
Asunto(s)
Acuaporina 2/metabolismo , Acuaporina 2/orina , Cromatografía Liquida , Diabetes Insípida/orina , Exosomas , Femenino , Humanos , Immunoblotting , Persona de Mediana Edad , Fosforilación/efectos de los fármacos , Espectrometría de Masas en Tándem , Vasopresinas/farmacologíaRESUMEN
OBJECTIVE: Diabetes insipidus (DI) and primary polydipsia (PP) are characterised by polyuria and polydipsia. It is crucial to differentiate between these two disorders since the treatment is different. The aim of this study was to evaluate the diagnostic value of the short and an extended variant of the water deprivation test (WDT) and of measuring urinary vasopressin (AVP) in patients with polyuria and polydipsia. DESIGN: A retrospective, single-centre study based on WDTs performed between 2004 and 2014 including 104 consecutive patients with the polyuria-polydipsia syndrome. During a strict water deprivation, weight, urinary osmolality, urinary vasopressin and specific gravity were collected until one of the following was reached: i) >3% weight reduction, ii) Urinary specific gravity >1.020 or, urinary osmolality >800 mOsm/L, iii) Intolerable adverse symptoms such as excessive thirst. RESULTS: Out of 104 patients (67 women, 37 men), 21 (20%) were diagnosed with DI and 83 (80%) with PP. The median (interquartile range; range) test duration was 14 hours (10-16; 3-36) in patients with DI and 18 hours (14-24; 7-48) in patients with PP (P=0.011). Of those diagnosed with PP, 22 (26%) did not reach urinary specific gravity >1.020 nor urine osmolality >800 mOsm/L. Urine AVP did not overlap between patients with PP and patients with central DI. CONCLUSIONS: The short WDT is of limited value in the diagnostic work-up of polydipsia and polyuria and a partial DI may have been missed in every fourth patient diagnosed with PP. Urinary AVP has excellent potential in discriminating PP from central DI.
Asunto(s)
Diabetes Insípida/diagnóstico , Neurofisinas/orina , Polidipsia Psicogénica/diagnóstico , Polidipsia/diagnóstico , Poliuria/diagnóstico , Precursores de Proteínas/orina , Vasopresinas/orina , Privación de Agua/fisiología , Adulto , Diabetes Insípida/sangre , Diabetes Insípida/orina , Femenino , Humanos , Masculino , Persona de Mediana Edad , Polidipsia/sangre , Polidipsia/orina , Polidipsia Psicogénica/sangre , Polidipsia Psicogénica/orina , Poliuria/sangre , Poliuria/orina , Valor Predictivo de las Pruebas , Estudios Retrospectivos , SíndromeRESUMEN
The extracellular domain of the (pro)renin receptor (PRR) is cleaved to produce a soluble (pro)renin receptor (sPRR) that is detected in biological fluid and elevated under certain pathological conditions. The present study was performed to define the antidiuretic action of sPRR and its potential interaction with liver X receptors (LXRs), which are known regulators of urine-concentrating capability. Water deprivation consistently elevated urinary sPRR excretion in mice and humans. A template-based algorithm for protein-protein interaction predicted the interaction between sPRR and frizzled-8 (FZD8), which subsequently was confirmed by coimmunoprecipitation. A recombinant histidine-tagged sPRR (sPRR-His) in the nanomolar range induced a remarkable increase in the abundance of renal aquaporin 2 (AQP2) protein in primary rat inner medullary collecting duct cells. The AQP2 up-regulation relied on sequential activation of FZD8-dependent ß-catenin signaling and cAMP-PKA pathways. Inhibition of FZD8 or tankyrase in rats induced polyuria, polydipsia, and hyperosmotic urine. Administration of sPRR-His alleviated the symptoms of diabetes insipidus induced in mice by vasopressin 2 receptor antagonism. Administration of the LXR agonist TO901317 to C57/BL6 mice induced polyuria and suppressed renal AQP2 expression associated with reduced renal PRR expression and urinary sPRR excretion. Administration of sPRR-His reversed most of the effects of TO901317. In cultured collecting duct cells, TO901317 suppressed PRR protein expression, sPRR release, and PRR transcriptional activity. Overall we demonstrate, for the first time to our knowledge, that sPRR exerts antidiuretic action via FZD8-dependent stimulation of AQP2 expression and that inhibition of this pathway contributes to the pathogenesis of diabetes insipidus induced by LXR agonism.
Asunto(s)
Diabetes Insípida/tratamiento farmacológico , Receptores Nucleares Huérfanos/metabolismo , Receptores de Superficie Celular/metabolismo , Orina/química , beta Catenina/metabolismo , Animales , Acuaporina 2/metabolismo , Diabetes Insípida/orina , Hidrocarburos Fluorados/farmacología , Receptores X del Hígado , Masculino , Ratones Endogámicos C57BL , Receptores Nucleares Huérfanos/agonistas , Ósmosis , Ratas Sprague-Dawley , Receptores de Superficie Celular/genética , Proteínas Recombinantes/genética , Proteínas Recombinantes/farmacología , Solubilidad , Sulfonamidas/farmacología , Orina/fisiología , Vía de Señalización Wnt , Receptor de ProreninaRESUMEN
OBJECTIVES: To review the incidence, spectrum of clinical manifestation, course, risk factors, as well as treatment of diabetes insipidus (DI) following neurosurgery of the pituitary gland. METHODS: The files of 24 patients that underwent neurosurgery for sellar lesions, or tumor near the hypothalamus or pituitary gland at the Department of Neurosurgery, King Abdulaziz University Hospital, Jeddah, Kingdom of Saudi Arabia were retrospectively reviewed between January 2011 to December 2014. A total of 24 patients were studied, and were divided into 2 groups namely; DI and non-DI. Patient characteristics were studied using descriptive statistics. The differences in proportion between the 2 groups were found out using Z-test for proportion in 2 populations. The mean differences in the hormonal abnormalities for the 2 groups were assessed using independent t-test. All statistics are considered statistically significant when p less than 0.05. RESULTS: During hospitalization, 13 (54.2%) out of 24 patient that underwent neurosurgery had manifestations of DI, which was transient in 5 (38.8%) and permanent in 8 (61.2%). The DI subgroup contained higher prevalence of prolactinoma, craniopharyngioma, pre-operative panhypopituitarism, and macroadenoma in MRI imaging and transphenoidal surgery. Furthermore, urine osmolality was significantly lower in the DI group post-operatively with a significant p=0.023. It was recognized that the permanent DI documented more significant numbers than other studies. CONCLUSION: In our study group, it was recognized that permanent DI meant that our patients needed desmopressin for more than 3 months, which documented a more significant number than other studies.
Asunto(s)
Craneofaringioma/cirugía , Diabetes Insípida/epidemiología , Hipopituitarismo/cirugía , Procedimientos Neuroquirúrgicos , Neoplasias Hipofisarias/cirugía , Complicaciones Posoperatorias/epidemiología , Prolactinoma/cirugía , Adenoma/diagnóstico por imagen , Adenoma/epidemiología , Adenoma/cirugía , Adulto , Craneofaringioma/epidemiología , Diabetes Insípida/orina , Femenino , Hospitales Universitarios , Humanos , Hipopituitarismo/epidemiología , Imagen por Resonancia Magnética , Masculino , Persona de Mediana Edad , Concentración Osmolar , Neoplasias Hipofisarias/diagnóstico por imagen , Neoplasias Hipofisarias/epidemiología , Complicaciones Posoperatorias/orina , Prevalencia , Prolactinoma/diagnóstico por imagen , Prolactinoma/epidemiología , Estudios Retrospectivos , Factores de Riesgo , Arabia Saudita/epidemiología , Adulto JovenRESUMEN
OBJECTIVE: Lithium continues to be an important mood disorder treatment. Although patients exposed to higher environmental temperatures may have serum lithium level elevations due to dehydration, there is conflicting data in the literature. In addition, no study has assessed the association between temperature and other renal laboratory tests and symptoms in lithium users. METHODS: This is a cross-sectional analysis of 63 current lithium users who participated in the McGill Geriatric Lithium-induced Diabetes Insipidus Clinical Study. The relationship between mean daily temperature with diabetes insipidus symptoms, glomerular filtration rate, urine osmolality, serum sodium, lithium level, and lithium dose-level ratio was assessed. RESULTS: Although a higher temperature on the day of laboratory testing trended toward being independently associated with a lower lithium dose-level ratio (Beta = -0.17, p = 0.08), this was not found when using a dichotomous measure of temperature (T > 20°C). No association was observed between temperature and other renal parameters. CONCLUSIONS: The association of temperature with lithium levels, renal symptoms, and laboratory tests appears to be of relatively little clinical importance in lithium users in temperate climates. However, future research should re-examine patients living in climates with extreme temperatures (e.g., >40°C), who may theoretically be at higher risk.
Asunto(s)
Diabetes Insípida/sangre , Diabetes Insípida/orina , Ambiente , Compuestos de Litio/sangre , Psicotrópicos/sangre , Temperatura , Adulto , Anciano , Anciano de 80 o más Años , Estudios Transversales , Diabetes Insípida/inducido químicamente , Tasa de Filtración Glomerular , Humanos , Modelos Lineales , Compuestos de Litio/efectos adversos , Compuestos de Litio/uso terapéutico , Masculino , Persona de Mediana Edad , Psicotrópicos/efectos adversos , Psicotrópicos/uso terapéutico , Sodio/sangre , Encuestas y Cuestionarios , Adulto JovenRESUMEN
Cerebral salt wasting syndrome (CSW-cerebral salt wasting) was first described in 1950 by Peters. This syndrome can occur in patients who have sustained damage to the central nervous system (e.g. patients with subarachnoid bleeding, bacterial meningitis or after neurosurgery). Patients present with excessive natriuresis and hyponatremic dehydration. Differentiating this syndrome with the syndrome of inappropriate antidiuretic hormone secretion (SIADH-syndrome of inappropriate antidiuretic hormone secretion), which may occur in the same group of patients, is necessary in order to administer the correct treatment which consists of fluid restriction and sodium replacement in SIADH and fluid and sodium replacement as well as occasional mineralocorticoid therapy in CSW.
Asunto(s)
Cerebro/metabolismo , Diabetes Insípida/sangre , Hiponatremia/sangre , Complicaciones Intraoperatorias , Complicaciones Posoperatorias/sangre , Sodio/sangre , Derivación Ventriculoperitoneal/efectos adversos , Adulto , Cerebro/cirugía , Diabetes Insípida/orina , Diagnóstico Diferencial , Humanos , Hiponatremia/orina , Complicaciones Posoperatorias/orina , Periodo Posoperatorio , Sodio/orina , Síndrome , Adulto JovenRESUMEN
Exosomes are vesicles that are released from the kidney into urine. They contain protein and RNA from the glomerulus and all sections of the nephron and represent a reservoir for biomarker discovery. Current methods for the identification and quantification of urinary exosomes are time consuming and only semi-quantitative. Nanoparticle tracking analysis (NTA) counts and sizes particles by measuring their Brownian motion in solution. In this study, we applied NTA to human urine and identified particles with a range of sizes. Using antibodies against the exosomal proteins CD24 and aquaporin 2 (AQP2), conjugated to a fluorophore, we could identify a subpopulation of CD24- and AQP2-positive particles of characteristic exosomal size. Extensive pre-NTA processing of urine was not necessary. However, the intra-assay variability in the measurement of exosome concentration was significantly reduced when an ultracentrifugation step preceded NTA. Without any sample processing, NTA tracked exosomal AQP2 upregulation induced by desmopressin stimulation of kidney collecting duct cells. Nanoparticle tracking analysis was also able to track changes in exosomal AQP2 concentration that followed desmopressin treatment of mice and a patient with central diabetes insipidus. When urine was stored at room temperature, 4°C or frozen, nanoparticle concentration was reduced; freezing at -80°C with the addition of protease inhibitors produced the least reduction. In conclusion, with appropriate sample storage, NTA has potential as a tool for the characterization and quantification of extracellular vesicles in human urine.
Asunto(s)
Exosomas , Nanopartículas/análisis , Adolescente , Adulto , Animales , Acuaporina 2/metabolismo , Biomarcadores/orina , Línea Celular , Desamino Arginina Vasopresina/farmacología , Diabetes Insípida/orina , Femenino , Humanos , Masculino , Ratones , Ratones Endogámicos C57BL , Nanopartículas/química , Tamaño de la Partícula , Urinálisis , Adulto JovenRESUMEN
In this report, we describe abrupt onset of secondary amenorrhea in a woman with history of chronic systemic sarcoidosis. Endocrinologic evaluation of her hypothalamic-pituitary axis revealed abnormally low levels of follicle-stimulating hormone, luteinizing hormone, and insulinlike growth factor 1 and elevated prolactin. Urine osmolality was low, and serum osmolality was high. Magnetic resonance imaging revealed diffuse extensive leptomeningeal enhancement, with involvement of the hypothalamus, pituitary stalk, and the optic chiasm. Clinical diagnosis was consistent with neurosarcoidosis with hypothalamic-pituitary infiltration resulting in clinical hypogonadotropic hypogonadism, hyper-prolactinemia, and diabetes insipidus. In our report, we provide an overview of basic reproductive neuroendocrinology and discuss salient concepts of the pathogenesis, clinical manifestations, evaluation, and management of hypogonadotropic hypogonadism. The current literature on neurosarcoidosis with involvement of the hypothalamic-pituitary axis is summarized. The possibility of infiltrative process should be considered in patients with new diagnosis of hypogonadotropic hypogonadal amenorrhea.
Asunto(s)
Amenorrea/etiología , Enfermedades del Sistema Nervioso Central/complicaciones , Enfermedades del Sistema Nervioso Central/diagnóstico , Hipogonadismo/etiología , Enfermedades de la Hipófisis/complicaciones , Enfermedades de la Hipófisis/diagnóstico , Sarcoidosis/complicaciones , Sarcoidosis/diagnóstico , Adulto , Enfermedades del Sistema Nervioso Central/sangre , Enfermedades del Sistema Nervioso Central/tratamiento farmacológico , Diabetes Insípida/complicaciones , Diabetes Insípida/orina , Estrógenos/uso terapéutico , Femenino , Hormona Folículo Estimulante/sangre , Humanos , Factor I del Crecimiento Similar a la Insulina/metabolismo , Hormona Luteinizante/sangre , Imagen por Resonancia Magnética , Concentración Osmolar , Enfermedades de la Hipófisis/sangre , Enfermedades de la Hipófisis/tratamiento farmacológico , Prolactina/sangre , Sarcoidosis/sangre , Sarcoidosis/tratamiento farmacológicoRESUMEN
It is known that n-3 polyunsaturated fatty acids (PUFAs), such as docosahexaenoic acid and eicosapentaenoic acid, are rapidly oxidized in vitro. Nvarepsilon-(propanoyl)lysine (propionyllysine, or PRL) is formed from the reaction of the oxidized products of n-3 PUFAs and lysine. To evaluate the oxidized n-3 PUFA-derived protein modifications in vivo, we have developed detection methods using a novel monoclonal antibody against PRL as well as liquid chromatography-mass spectrometry (LC/MS/MS). The antibody obtained specifically recognized PRL. A strong positive staining in atherosclerotic lesions of hypercholesterolemic rabbits was observed. We have also simultaneously identified and quantified both urinary PRL and urinary Nvarepsilon-(hexanoyl)lysine, using LC/MS/MS using isotope dilution methods. The level of urinary PRL (21.6+/-10.6 micromol/mol of creatinine) significantly correlated with the other oxidative stress markers, 8-oxo-deoxyguanosine, dityrosine, and isoprostanes. The increase in the excretion of amide adducts into the urine of diabetic patients was also confirmed compared to healthy subjects. These results suggest that PRL may be good marker for n-3 PUFA-derived oxidative stress in vivo.
Asunto(s)
Aorta/metabolismo , Enfermedad de la Arteria Coronaria/metabolismo , Hipercolesterolemia/metabolismo , Propionatos/química , Propionatos/inmunología , 8-Hidroxi-2'-Desoxicoguanosina , Animales , Anticuerpos Monoclonales/inmunología , Aorta/inmunología , Aorta/patología , Biomarcadores/orina , Enfermedad de la Arteria Coronaria/inmunología , Enfermedad de la Arteria Coronaria/patología , Desoxiguanosina/análogos & derivados , Desoxiguanosina/orina , Diabetes Insípida/fisiopatología , Diabetes Insípida/orina , Dinoprost/análogos & derivados , Dinoprost/orina , Ácidos Grasos Insaturados/química , Ácidos Grasos Insaturados/metabolismo , Humanos , Hipercolesterolemia/inmunología , Hipercolesterolemia/patología , Inmunoquímica , Lisina/análogos & derivados , Lisina/química , Lisina/inmunología , Lisina/metabolismo , Espectrometría de Masas , Oxidación-Reducción , Estrés Oxidativo , Propionatos/metabolismo , ConejosRESUMEN
Diabetes insipidus is a clinical entity that is often seen in neurosurgical patients either during or immediately after transsphenoidal hypophysectomy. Rarely, diabetes insipidus can manifest as a new entity months later in patients who have previously had an intracranial injury or operation.
Asunto(s)
Anestésicos Intravenosos/efectos adversos , Diabetes Insípida/inducido químicamente , Hipofisectomía/efectos adversos , Propofol/efectos adversos , Tiroidectomía/efectos adversos , Adolescente , Anestésicos Intravenosos/administración & dosificación , Diabetes Insípida/orina , Humanos , Masculino , Concentración Osmolar , Propofol/administración & dosificación , Resultado del TratamientoRESUMEN
Peptides with agonist activity at the vasopressin V(2) receptor are used clinically to treat fluid homeostasis disorders such as polyuria and central diabetes insipidus. Of these peptides, the most commonly used is desmopressin, which displays poor bioavailability as well as potent activity at the V(1b) receptor, with possible stress-related adverse effects. Thus, there is a strong need for the development of small molecule chemistries with selective V(2) receptor agonist activity. Using the functional cell-based assay Receptor Selection and Amplification Technology (R-SAT((R))), a screening effort identified three small molecule chemotypes (AC-94544, AC-88324, and AC-110484) with selective agonist activity at the V(2) receptor. One of these compounds, AC-94544, displayed over 180-fold selectivity at the V(2) receptor compared to related vasopressin and oxytocin receptors and no activity at 28 other G protein-coupled receptors (GPCRs). All three compounds also showed partial agonist activity at the V(2) receptor in a cAMP accumulation assay. In addition, in a rat model of central diabetes insipidus, AC-94544 was able to significantly reduce urine output in a dose-dependent manner. Thus, AC-94544, AC-88324, and AC-110484 represent novel opportunities for the treatment of disorders associated with V(2) receptor agonist deficiency.
Asunto(s)
Preparaciones Farmacéuticas/síntesis química , Preparaciones Farmacéuticas/metabolismo , Receptores de Vasopresinas/agonistas , Receptores de Vasopresinas/metabolismo , Animales , Fármacos Antidiuréticos/administración & dosificación , Fármacos Antidiuréticos/síntesis química , Desamino Arginina Vasopresina/administración & dosificación , Desamino Arginina Vasopresina/química , Desamino Arginina Vasopresina/metabolismo , Desamino Arginina Vasopresina/uso terapéutico , Diabetes Insípida/prevención & control , Diabetes Insípida/orina , Relación Dosis-Respuesta a Droga , Humanos , Masculino , Ratones , Células 3T3 NIH , Péptidos/química , Péptidos/metabolismo , Péptidos/farmacología , Péptidos/uso terapéutico , Preparaciones Farmacéuticas/administración & dosificación , Ratas , Ratas Brattleboro , Vasopresinas/deficiencia , Vasopresinas/genética , Vasopresinas/metabolismo , Vasopresinas/uso terapéuticoRESUMEN
The diagnosis of cystic fibrosis (CF) can be confusing when only a part of the typical symptoms is present. In children, CF is usually suspected when dealing with chronic pulmonary symptoms (chronic productive cough, recurrent pneumonia or bronchiolitis). The pediatric gastroenterologist will exclude CF in all children with a meconium ileus, rectal prolaps or a poor weight gain. Atypical CF symptoms are hypochloremic alkalosis, recurrent pancreatitis and increased appetite to compensate for the pancreatic insufficiency. This case report shows how a diagnosis can be delayed when you are mislead by atypical symptoms. It shows the importance of looking in napkins and argues for the inclusion of CF in the differential diagnosis of polyuria in infants.
Asunto(s)
Fibrosis Quística/diagnóstico , Desamino Arginina Vasopresina/uso terapéutico , Diabetes Insípida/diagnóstico , Fármacos Antidiuréticos/uso terapéutico , Diabetes Insípida/orina , Diagnóstico Diferencial , Heces/enzimología , Femenino , Estudios de Seguimiento , Humanos , Lactante , Concentración Osmolar , Elastasa Pancreática/análisis , Esteatorrea/diagnósticoRESUMEN
When a patient with diabetes mellitus presents with worsening polyuria and polydipsia, what is a sensible, cost-effective approach? We report the unique coincidence of type 2 diabetes mellitus and diabetes insipidus. A 46-year-old woman with poorly controlled type 2 diabetes complained of polyuria with a daily output of 5 L. Although urinalysis demonstrated significant glucosuria, diabetes insipidus was suspected owing to a low urine specific gravity (1.008). The low specific gravity persisted during a water deprivation test. Ultimately, diabetes insipidus was confirmed when urine specific gravity and urine osmolality normalized following desmopressin administration. This case emphasizes the importance of accurately interpreting the urine specific gravity in patients with polyuria and diabetes mellitus to detect diabetes insipidus.
Asunto(s)
Diabetes Insípida/diagnóstico , Diabetes Insípida/orina , Diabetes Mellitus Tipo 2/diagnóstico , Diabetes Mellitus Tipo 2/orina , Diabetes Insípida/complicaciones , Diabetes Mellitus Tipo 2/complicaciones , Diagnóstico Diferencial , Femenino , Humanos , Persona de Mediana Edad , Poliuria/complicaciones , Poliuria/diagnóstico , Poliuria/orina , Gravedad Específica , Urinálisis/métodosRESUMEN
BACKGROUND: The antidiuretic effect of oxytocin in humans is controversial. Urinary excretion of aquaporin-2 (AQP2) can be used as an index of the action of vasopressin on the kidney. We investigated whether exogenous oxytocin affects urinary concentration and urinary AQP2 excretion in human beings. METHODS: Oxytocin was administered intravenously at a rate of 20 mU/min in 10 healthy volunteers, seven patients with central diabetes insipidus (CDI) and three patients with nephrogenic diabetes insipidus (NDI). On the next day, 2 micro g of 1-desamino-8-d-arginine vasopressin (dDAVP) was injected subcutaneously. Two-hour urine was collected before and after the administration of oxytocin and dDAVP, and urinary AQP2 was measured semi-quantitatively by western analysis. RESULTS: Urine volume and free water clearance were decreased, and urine osmolality was increased by the administration of oxytocin or dDAVP in the normal volunteers and CDI patients. Urinary AQP2 excretion was increased by oxytocin infusion in the normal volunteers (from 34+/-12 to 326+/-120 densitometry unit (DU)/2 h) and in the CDI group (from 8+/-2 to 227+/-92 DU/2 h) (P<0.05), but not in the NDI group. dDAVP also had a similar but more potent effect on the urinary excretion of AQP2 in the normal and CDI groups. CONCLUSIONS: Oxytocin has an antidiuretic effect and increases the urinary excretion of AQP2 in humans whose urinary concentration mechanism is preserved. These results suggest that AQP2 might have a regulatory role in the antidiuretic action of oxytocin in humans.
Asunto(s)
Acuaporinas/orina , Diabetes Insípida Nefrogénica/fisiopatología , Diabetes Insípida/fisiopatología , Diuresis/efectos de los fármacos , Oxitocina/farmacología , Adulto , Acuaporina 2 , Desamino Arginina Vasopresina/farmacología , Diabetes Insípida/orina , Diabetes Insípida Nefrogénica/orina , Humanos , Immunoblotting , Infusiones Intravenosas , Masculino , Concentración Osmolar , Oxitocina/administración & dosificación , Fármacos Renales/farmacologíaRESUMEN
BACKGROUND: An increase in urinary albumin excretion (UAE) represents an early predictor of glomerular damage in diabetes mellitus (DM) and a risk factor for cardiovascular complications in hypertension. Vasopressin is elevated in DM and in some forms of hypertension. Previous studies in rats suggested that this hormone could play a role in the albuminuria observed in chronic renal failure or diabetic nephropathy, but no information is available concerning the mechanism of these effects and the possible influence of vasopressin on UAE in the healthy kidney. The present study was thus designed to evaluate whether vasopressin influences UAE in normal rats and humans, whether this effect is V(2)-receptor-dependent, and whether it is mediated by the renin-angiotensin system. METHODS: UAE was measured in normal Wistar rats and healthy humans, or in subjects with various forms of diabetes insipidus (DI), before and after acute or chronic infusion of the vasopressin V(2) receptor agonist dDAVP. Chronic dDAVP administration was also performed in normal Wistar rats previously submitted to either chronic angiotensin-converting enzyme inhibition (ACEI) or chronic blockade of AT1 receptors (ARB). RESULTS: In rats, acute or chronic dDAVP infusion increased UAE significantly and reversibly (4-fold and 6-fold, respectively). In healthy subjects, acute infusion of dDAVP tripled UAE (P<0.01) but did not change creatinine and beta(2)-microglobulin excretion, thus suggesting that the rise in UAE was due to an increased glomerular leakage of albumin. dDAVP also increased UAE in patients with central DI and in patients with hereditary nephrogenic DI bearing AQP2 mutations. However, UAE was not increased in patients with hereditary nephrogenic DI bearing mutations of the V(2) receptor. In rats, ACEI and ARB blunted the dDAVP-induced rise in UAE by 70% (P<0.05) and 50% (NS), respectively. CONCLUSIONS: The present studies reveal for the first time that vasopressin induces a marked increase in UAE in healthy rats and humans. This albuminuric effect seems to result from increased glomerular leakage, requires functional vasopressin V(2) receptors, and is, at least in part, mediated by the renin-angiotensin system. These results bring additional support for an involvement of vasopressin in the albuminuria observed in pathological states such as diabetes mellitus or hypertension.
Asunto(s)
Albuminuria/inducido químicamente , Albuminuria/fisiopatología , Desamino Arginina Vasopresina/efectos adversos , Diabetes Insípida/fisiopatología , Receptores de Vasopresinas/fisiología , Fármacos Renales/efectos adversos , Sistema Renina-Angiotensina/fisiología , Vasopresinas/efectos adversos , Adulto , Albuminuria/orina , Animales , Presión Sanguínea/fisiología , Diabetes Insípida/orina , Femenino , Humanos , Masculino , Ratas , Valores de ReferenciaRESUMEN
OBJECTIVE: To re-examine the controversial possibility that prolactin exerts renal effects, using recombinant mouse prolactin (rmP), in the presence and absence of circulating vasopressin. DESIGN: In experiment 1, the renal effects of rmP were examined in anaesthetized Brattleboro rats with hereditary hypothalamic diabetes insipidus (BDI) lacking circulating vasopressin and normal animals of the parent Long Evans (LE) strain. In experiment 2, salt and water excretion were studied in fluid-loaded normal Sprague-Dawley (SD) rats, some of which received rmP. METHODS: In experiment 1, BDI and LE rats maintained in fluid balance were infused i.v. with each of three concentrations of rmP (10, 20 and 40 microg/ml per h) or maintained on 150 mmol/l NaCl vehicle (controls). In experiment 2, the SD rats were infused with 75 mmol/l NaCl in order to induce a state of diuresis comparable to that of BDI rats, some of them then receiving the rmP i.v. RESULTS: A profound rmP-induced dose-dependent decrease in urine excretion (P<0.005) and a lesser decrease in sodium excretion in the BDI rats was in marked contrast with the small but significant increase in urine excretion in the LE rats compared with controls (P<0.025). The rmP-infused fluid-loaded SD rats also demonstrated a significant (P<0.05) dose-related antidiuresis compared with the control animals, in addition to a decrease in sodium excretion. CONCLUSIONS: These results show that prolactin has a profound antidiuretic effect in the absence of circulating vasopressin. In contrast, when vasopressin is present in the circulation rmP has a small, but opposite, diuretic effect. Thus the use of a recombinant prolactin has provided evidence for renal effects of this hormone which are modified in the presence of the circulating neurohypophysial hormone vasopressin.
Asunto(s)
Riñón/efectos de los fármacos , Prolactina/farmacología , Anestésicos Intravenosos/administración & dosificación , Animales , Diabetes Insípida/sangre , Diabetes Insípida/fisiopatología , Diabetes Insípida/orina , Riñón/fisiología , Riñón/fisiopatología , Masculino , Potasio/sangre , Potasio/orina , Prolactina/administración & dosificación , Ratas , Ratas Brattleboro , Ratas Long-Evans , Ratas Sprague-Dawley , Proteínas Recombinantes/administración & dosificación , Proteínas Recombinantes/farmacología , Sodio/sangre , Sodio/orina , Tiopental/administración & dosificación , Micción/efectos de los fármacos , Micción/fisiología , Vasopresinas/fisiologíaRESUMEN
Studies were undertaken in a 32-year-old man who developed polyuria (4 L/d) a few days after a basal skull fracture; the condition persisted 1 year after the accident. The other major features were thirst, a plasma sodium of 143 mmol/L, 24-hour urine osmolality of 221 mOsm/kg H(2)O, and levels of vasopressin in plasma that were less than 0.5 pg/mL on 20 separate occasions. The 24-hour urine volume implied that the diagnosis was partial rather than complete central diabetes insipidus; however, several random urine samples had a much higher osmolality. An infusion of hypertonic saline led to the release of vasopressin and the excretion of concentrated urine. We propose that the basis for the lesion may be the transection of some, but not all, of the fibers connecting the osmostat and vasopressin release center. This partial transection could permit vasopressin to be secreted in response to a larger rise in plasma sodium concentration. This pathophysiologic analysis provided the basis for therapy to minimize the degree of polyuria.
Asunto(s)
Diabetes Insípida/orina , Poliuria/terapia , Adulto , Diabetes Insípida/fisiopatología , Humanos , Masculino , SedRESUMEN
BACKGROUND: In a previous study we observed that acute administration of the selective antagonist of vasopressin (AVP) V2 receptors, SR 121463A (SR), aggravated the symptoms of diabetes insipidus (DI) in homozygous Brattleboro rats (an AVP-deficient strain). The present study investigates in more details the acute and chronic effects of SR in DI rats. METHODS AND RESULTS: In experiment A, different groups of rats received acute i.p. injections of SR (0.001-10 mg/kg) or vehicle alone, and urine was collected for the next 24 h. SR dose-dependently increased urine flow rate and decreased urine osmolality with no significant change in solute excretion, thus confirming a pure 'aquaretic' effect. In experiments B and C, the chronic effects of orally administered SR were evaluated over 8 days in Brattleboro DI rats (experiment B, 1 mg/kg/day) and in adult Sprague-Dawley rats with normal AVP secretion (experiment C, 3 mg/kg/day). In DI rats, the aquaretic effects of SR persisted with the same intensity over the 8 days. In Sprague-Dawley rats, SR induced a sustained, stable aquaretic effect and also increased non-renal water losses, suggesting an effect of AVP on water conservation in extrarenal sites. Because oxytocin (OT) synthesis is elevated in DI rats and OT is known to bind to V2 receptors, we evaluated the antidiuretic effects of OT in DI rats in experiment D. Chronic infusion of OT (3 microg/kg/h, i.p.) induced a marked antidiuresis, and acute SR (1 mg/kg) in OT-treated DI rats completely abolished this antidiuretic effect, thus indicating that it was due to binding of OT to V2 receptors. CONCLUSION: (i) SR is a potent orally active aquaretic and induces stable effects during 1 week in rats with or without endogenous AVP secretion. (ii) Significant V2 receptor-mediated water reabsorption occurs in collecting ducts of Brattleboro DI rats because their usual urine osmolality is about twofold higher than the minimum observed during SR-induced maximum diuresis. (iii) This V2 agonism could be mediated in part by OT binding to V2 receptors. Small amounts of endogenous AVP, known to be produced by adrenal and testis in DI rats, could also contribute to this V2 agonism, as well as a possible constitutive activation of the V2 receptors. (iv) In normal rats, AVP probably reduces water losses through extrarenal sites, probably the lungs.
Asunto(s)
Antagonistas de los Receptores de Hormonas Antidiuréticas , Diabetes Insípida/orina , Morfolinas/farmacología , Compuestos de Espiro/farmacología , Animales , Masculino , Ratas , Vasopresinas/metabolismo , Vasopresinas/farmacología , Agua/metabolismoRESUMEN
Aquaporin-2 (AQP-2) is an arginine vasopressin (AVP)-regulated water channel in renal collecting duct cells. Approximately 3 % of AQP-2 in collecting duct cells is excreted into urine. Urinary excretion of AQP-2 varies widely in different physiological conditions, and it has a positive correlation with plasma AVP levels. Urinary excretion of AQP-2 was significantly increased by the single injection of AVP in patients with central diabetes insipidus. The urinary excretion of AQP-2 was one-eighth over in patients with central diabetes insipidus and three times greater in patients with impaired water excretion than that in normal subjects. In a hypertonic saline test, the urinary excretion of AQP-2 promptly increased 6-12-fold in normal subjects, but remained low in patients with central diabetes insipidus. In addition, exaggerated urinary excretion of AQP-2 persisted after an acute water load in patients with impaired water excretion. These results indicate that urinary excretion of AQP-2 is a potent marker for the diagnosis of water metabolism disorders dependent on AVP.